<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03283787</url>
  </required_header>
  <id_info>
    <org_study_id>CA2016-001</org_study_id>
    <nct_id>NCT03283787</nct_id>
  </id_info>
  <brief_title>Comparing Concomitant Use of ACell MicroMatrix® and ACell Cytal™ to Standard of Care in Stage 3 or 4 Pressure Injuries</brief_title>
  <official_title>A Single Site Randomized, Clinical Trial Comparing the Concomitant Use of MicroMatrix® With Cytal™ Wound Matrix 2-Layer to Standard of Care in Patients With Stage 3 or 4 Pressure Injuries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ACell Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Vincent's Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ACell Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate incidence of complete epithelialization in stage 3 &amp;
      4 pressure ulcers using ACell products.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A three arm, parallel-design, randomized study comparing 2 experimental arms to a single
      control arm. The primary comparison will be Group 1 (MicroMatrix® and ACell Cytal™ Wound
      Matrix 2-Layer vs. Group 3 (NPWT) to determine if Group 1 is superior to Group 3. NPWT is the
      standard of care (SOC) for patients with Stage 3 or 4 pressure ulcers and is the active
      control arm for the study.

      A secondary comparison will be conducted comparing Group 2 (MicroMatrix® and ACell Cytal™
      Wound Matrix 2-Layer plus NPWT) vs. Group 3 (NPWT) to determine if Group 2 is superior to
      Group 3.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of complete epithelization</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence of complete epithelization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to complete wound epithelization</measure>
    <time_frame>12 weeks</time_frame>
    <description>Time to complete wound epithelization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of wound epithelization</measure>
    <time_frame>12 weeks</time_frame>
    <description>Rate of wound epithelization</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pressure Ulcers Stage III</condition>
  <condition>Pressure Ulcer, Stage IV</condition>
  <condition>Pressure Ulcer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MicroMatrix® and Cytal™ Wound Matrix 2-Layer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Negative Pressure Wound Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MicroMatrix® and Cytal™ Wound Matrix 2-Layer</intervention_name>
    <description>MicroMatrix® and Cytal™ Wound Matrix 2-Layer</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT</intervention_name>
    <description>MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Negative Pressure Wound Therapy</intervention_name>
    <description>Negative Pressure Wound Therapy</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients that are ≥ 21 years of age.

          2. Body Mass Index (BMI) &lt;45.

          3. At least one Stage 3 or 4 pressure injury (NPUAP Staging Guidelines) present at the
             Screening and/or Treatment Visit.

          4. Surface dimensions of pressure injury must be between 9 to 64 cm2 inclusive. The
             longest dimension must not exceed 10 cm; depth must not exceed 5 cm.

          5. Wound must be &gt;5 cm from the anus if colostomy not performed.

          6. For lower extremity ulcers: Adequate arterial blood flow and perfusion near the site
             of the injury.

          7. Confirmed pressure injury versus moisture-associated skin damage or friction injury.

          8. Negative pregnancy test required.

        Exclusion Criteria:

          1. Surgical treatment of pressure injury 30 days prior to Treatment Visit and/or pressure
             injury in previously irradiated areas.

          2. Inability to manage fecal and/or urine incontinence or patient refusal of its
             maintenance/management.

          3. Allergy or hypersensitivity to materials in porcine-based study products or personal
             preference.

          4. Currently treated for an active malignant disease.

          5. Prior diagnosis of active malignant disease, and is less than 1 year disease-free.

          6. History of malignancy within the wound.

          7. Bleeding diathesis.

          8. Received biological-based therapy in any pressure wound within 3 months of the
             Treatment Visit.

          9. Severe or significant hypoalbuminemia or hypoproteinemia.

         10. Moderate to severe anemia.

         11. Severely uncontrolled diabetes mellitus.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol Bowen-Wells, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Vincent's Medical Center Riverside</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Warren, RN, MA</last_name>
    <phone>443-283-2885</phone>
    <email>jessicawarren@acell.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth Smith</last_name>
    <phone>443-283-2768</phone>
    <email>elizabethsmith@acell.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Saint Vincent's Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Bowen-Wells, MD</last_name>
      <phone>904-503-8335</phone>
      <email>carol.bwells@wsrfi.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2017</study_first_submitted>
  <study_first_submitted_qc>September 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2017</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pressure Ulcer</keyword>
  <keyword>ACell</keyword>
  <keyword>ACell MicroMatrix®</keyword>
  <keyword>ACell Cytal™</keyword>
  <keyword>Extracellular Matrix</keyword>
  <keyword>Urinary Bladder Matrix</keyword>
  <keyword>Wound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Pressure Ulcer</mesh_term>
    <mesh_term>Crush Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share individual participant data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

